India, Oct. 16 -- Fractyl Health, Inc. (GUTS) is down 48.43 percent, losing $2.0190 to $2.1410 on Friday. The plunge comes despite the company reporting positive six-month results from the pivotal cohort of its REMAIN-1 study evaluating the Revita DMR System for weight maintenance after discontinuation of GLP-1 therapy. The study met its pre-specified six-month co-primary endpoint, with Revita significantly reducing weight regain compared with sham treatment.
Fractyl Health is currently trading at $2.1410, down from the previous close of $4.1600 after opening at $2.1200 on the Nasdaq. The stock has traded between $2.0200 and $2.3000 during the session. Trading volume has surged to 10.59 million shares, compared with average volume of about...